AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25027640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2. mA) over the left primary motor area (M1) for 20 minutes
Number of subjects: 20
Study 25027640 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 24858755 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) followed by placement of Atridox gel (10% doxycycline hyclate)
Number of subjects: 12
Study 24858755 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 12
Study 21732954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-reinforced composite (FRC)/Duolink resin cement
Number of subjects: 90
Study 21732954 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta-percha/AH Plus
Number of subjects: 90
Study 21732954 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 90
Study 21732954 — intervention group
Group type: EXPERIMENTAL
Intervention: Plunger diameter 1.25 mm (FRC group)
Number of subjects: 90
Study 21732954 — intervention group
Group type: EXPERIMENTAL
Intervention: Plunger diameter 0.75 mm and 1 mm (FRC group)
Number of subjects: 90
Study 19628729 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (100 mg/25 mg bid)
Number of subjects: 24
Study 19628729 — intervention group
Group type: EXPERIMENTAL
Intervention: rotigotine (initial dose 2 mg/24 h for 3 days, followed by 4 mg/24 h)
Number of subjects: 24
Study 19628729 — intervention group
Group type: COMPARATOR
Intervention: Combination of levodopa/carbidopa and rotigotine
Number of subjects: 24
Study 16496410 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 1805
Study 16496410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1805
Study 15134155 — intervention group
Group type: EXPERIMENTAL
Intervention: FertilityBlend (nutritional supplement)
Number of subjects: 30
Study 15134155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10518174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 97
Study 10518174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline + Group Cognitive Behavior Therapy
Number of subjects: 97
Study 10518174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy
Number of subjects: 97
Study 10518174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7758060 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg BID
Number of subjects: 930
Study 7758060 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg BID
Number of subjects: 930
Study 2320558 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure feedback
Number of subjects: 40
Study 2320558 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure feedback
Number of subjects: 40
Study 448576 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg)
Number of subjects: 9
Study 448576 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.25 mg/kg)
Number of subjects: 9
Study 448576 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.3 mg/kg)
Number of subjects: 9
Study 448576 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (all doses)
Number of subjects: 9
Study 31920295 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6μg
Number of subjects: 416
Study 27881011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combined with bevacizumab intraperitoneal (i.p.)
Number of subjects: 0
Study 27881011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combined with bevacizumab intravenous (i.v.)
Number of subjects: 0
Study 27881011 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy only
Number of subjects: 0
Study 24729134 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental exposure to non-violent pornography
Number of subjects: 200
Study 24729134 — intervention group
Group type: EXPERIMENTAL
Intervention: Past pornography consumption
Number of subjects: 200
Study 24729134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of agreeableness
Number of subjects: 200
Study 24729134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual arousal (mediating effect)
Number of subjects: 200
Study 24363218 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended electromyostimulation (exEMS)
Number of subjects: 31
Study 24363218 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited electromyostimulation (limEMS)
Number of subjects: 31
Study 22628120 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin clavulanate (22.5 mg/kg/dose, twice daily for 2 weeks)
Number of subjects: 50
Study 22628120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22628120 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin clavulanate
Number of subjects: 50
Study 19716960 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once per day)
Number of subjects: 3091
Study 19716960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3091
Study 17887949 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day silymarin
Number of subjects: 59
Study 17887949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17887949 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide alone
Number of subjects: 59
Study 15202038 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor specific assignment
Number of subjects: 309
Study 15202038 — intervention group
Group type: COMPARATOR
Intervention: Conventional assignment
Number of subjects: 309
Study 12231521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (1 x 10(6) IU/m(2)/day s.c. for 90 days)
Number of subjects: 35
Study 12231521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 with intermediate pulse doses (6-12 x 10(6) IU/m(2)/day s.c. for 3 days every 14 days, maximum five pulses)
Number of subjects: 35
Study 12231521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 with or without intermediate pulse dose therapy
Number of subjects: 35
Study 12231521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 with intermediate pulse doses
Number of subjects: 35
Study 12231521 — intervention group
Group type: EXPERIMENTAL
Intervention: NKG2D ligands expression in leukemic cells
Number of subjects: 35
Study 9824783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 1,000 mg six times a day
Number of subjects: 22
Study 9824783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 1,500 mg four times a day
Number of subjects: 22
Study 9824783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 2,000 mg three times a day
Number of subjects: 22
Study 8084907 — intervention group
Group type: COMPARATOR
Intervention: Medium-fat/medium-carbohydrate (MFMC) lunch (45% fat, 42% carbohydrate, 12% protein)
Number of subjects: 18
Study 8084907 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/high-carbohydrate (LFHC) lunch (29% fat, 54% carbohydrate, 15% protein)
Number of subjects: 18
Study 8084907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/low-carbohydrate (HFLC) lunch (62% fat, 24% carbohydrate, 13% protein)
Number of subjects: 18
Study 2789919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide 25 micrograms
Number of subjects: 12
Study 2789919 — intervention group
Group type: COMPARATOR
Intervention: Timolol 20 mg (positive control)
Number of subjects: 12
Study 31132996 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered psycho-behavioural intervention
Number of subjects: 236
Study 31132996 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological behavioural support (during maintenance phase)
Number of subjects: 236
Study 31132996 — intervention group
Group type: COMPARATOR
Intervention: Regular telephone contacts from counsellors (control group during intensive phase)
Number of subjects: 236
Study 31132996 — intervention group
Group type: COMPARATOR
Intervention: Regular telephone contacts from counsellors (control group during maintenance phase)
Number of subjects: 236
Study 29223427 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoue technique
Number of subjects: 302
Study 29223427 — intervention group
Group type: COMPARATOR
Intervention: double-balloon technique
Number of subjects: 302
Study 26350766 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 57
Study 26350766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24704893 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy tools (Ask Me 3™, Four Habits Model, Teach-back)
Number of subjects: 160
Study 22860014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade with enalapril (20 mg o.d.) and candesartan (16 mg o.d.)
Number of subjects: 67
Study 22860014 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with enalapril or candesartan
Number of subjects: 67
Study 19010583 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of IL-8
Number of subjects: 13
Study 19010583 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of IL-6
Number of subjects: 13
Study 19010583 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale (GOS) score at 6 months after ROSC
Number of subjects: 13
Study 19010583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff values for IL-8
Number of subjects: 13
Study 19010583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff values for IL-6
Number of subjects: 13
Study 18173005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactofem (viable Lactobacilli)
Number of subjects: 32
Study 18173005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15121053 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparkinsonian medication
Number of subjects: 0
Study 15121053 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet analysis of EMG signals
Number of subjects: 0
Study 11290882 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 15
Study 11290882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9926909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 410
Study 9926909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 8067592 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 167
Study 8067592 — intervention group
Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 167
Study 3177010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bromocriptine
Number of subjects: 119
Study 3177010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 119
Study 31833918 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's concerns related to their mother's breast cancer diagnosis
Number of subjects: 140
Study 30894306 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Sided Game (SSG) training
Number of subjects: 20
Study 30894306 — intervention group
Group type: COMPARATOR
Intervention: Generic Fitness Training (GFT)
Number of subjects: 20
Study 28753863 — intervention group
Group type: EXPERIMENTAL
Intervention: NSS
Number of subjects: 541
Study 28753863 — intervention group
Group type: COMPARATOR
Intervention: RN
Number of subjects: 541
Study 26001717 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychoeducation program
Number of subjects: 82
Study 26001717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 25931327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) alone
Number of subjects: 219
Study 25931327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements alone
Number of subjects: 219
Study 25931327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and nutrition
Number of subjects: 219
Study 25931327 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 219
Study 21453368 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-tip catheter (LTC)
Number of subjects: 60
Study 21453368 — intervention group
Group type: COMPARATOR
Intervention: Open-irrigation-tip catheter (OITC)
Number of subjects: 60
Study 17641378 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA-PEI
Number of subjects: 133
Study 17641378 — intervention group
Group type: COMPARATOR
Intervention: RFA alone
Number of subjects: 133
Study 16227417 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa resort treatment
Number of subjects: 120
Study 16227417 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation hospital)
Number of subjects: 120
Study 12044434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 30
Study 12044434 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 30
Study 12044434 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cross‐clamp fibrillation (ICCF)
Number of subjects: 30
Study 10458255 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel treatment algorithm based on the Agency for Health Care Policy and Research Guidelines for Cancer Pain Management
Number of subjects: 81
Study 10458255 — intervention group
Group type: COMPARATOR
Intervention: Standard‐practice pain and symptom management therapies
Number of subjects: 81
Study 7842187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (mean 10.1 mg daily)
Number of subjects: 34
Study 7842187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (15 mg daily for 7 days)
Number of subjects: 34
Study 7842187 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (500 micrograms twice daily for 7 days)
Number of subjects: 34
Study 7842187 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not taking oral steroids)
Number of subjects: 34
Study 2145871 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 69,578 (10 mg/kg)
Number of subjects: 16
Study 2145871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2145871 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 69,578 (0.025 to 10.0 mg/kg)
Number of subjects: 16
Study 2145871 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 69,578
Number of subjects: 16
Study 861153 — intervention group
Group type: EXPERIMENTAL
Intervention: isoetharine or isoprenaline
Number of subjects: 17
Study 861153 — intervention group
Group type: COMPARATOR
Intervention: sodium cromoglycate
Number of subjects: 17
Study 28869786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dose of lorazepam
Number of subjects: 13
Study 28869786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg dose of lorazepam
Number of subjects: 13
Study 28869786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg dose of lorazepam
Number of subjects: 13
Study 28869786 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg dose of lorazepam
Number of subjects: 13
Study 27278276 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week home-based exercise intervention consisting of 45 minutes of moderate-intensity (60-65% peak oxygen uptake) arm-crank exercise four times per week
Number of subjects: 0
Study 27278276 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle maintenance (Control group)
Number of subjects: 0
Study 24342775 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 33
Study 24342775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 22321963 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Number of subjects: 451
Study 22321963 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 451
Study 21194249 — intervention group
Group type: EXPERIMENTAL
Intervention: Meriva® (curcumin-phosphatidylcholine complex)
Number of subjects: 100
Study 21194249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 18528401 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil citrate
Number of subjects: 601
Study 15986954 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ1 + SureFil
Number of subjects: 60
Study 15986954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop + SureFil with flowable resin composite
Number of subjects: 60
Study 15986954 — intervention group
Group type: COMPARATOR
Intervention: SureFil
Number of subjects: 60
Study 15986954 — intervention group
Group type: COMPARATOR
Intervention: PermaFlo + SureFil
Number of subjects: 60
Study 15986954 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 60
Study 15986954 — intervention group
Group type: COMPARATOR
Intervention: Air‐abrasive technique
Number of subjects: 60
Study 12682621 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose losartan (100 mg/day)
Number of subjects: 40
Study 12682621 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg/day)
Number of subjects: 40
Study 12682621 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive rHuEPO dependent patients)
Number of subjects: 40
Study 10726921 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg vanadyl sulfate (VOSO4)
Number of subjects: 16
Study 10726921 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg vanadyl sulfate (VOSO4)
Number of subjects: 16
Study 10726921 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg and 300 mg vanadyl sulfate (VOSO4)
Number of subjects: 16
Study 10726921 — intervention group
Group type: EXPERIMENTAL
Intervention: vanadyl sulfate
Number of subjects: 16
Study 8934373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (2-6 mg)
Number of subjects: 16590
Study 8934373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 16590
Study 1527233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally followed by adinazolam 30 mg 1 hour later (treatment A)
Number of subjects: 12
Study 1527233 — intervention group
Group type: COMPARATOR
Intervention: Adinazolam alone (treatment B)
Number of subjects: 12
Study 4014629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meptazinol 2 mg/kg
Number of subjects: 64
Study 4014629 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 64
Study 28467137 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive disclosure
Number of subjects: 64
Study 28467137 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit finding
Number of subjects: 64
Study 28467137 — intervention group
Group type: COMPARATOR
Intervention: Time-management control
Number of subjects: 64
Study 28467137 — intervention group
Group type: EXPERIMENTAL
Intervention: All writing conditions
Number of subjects: 64
Study 26059860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF)
Number of subjects: 154
Study 26059860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir + Ribavirin (LDV/SOF + RBV)
Number of subjects: 154
Study 26059860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 26059860 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful viral clearance (N = 149)
Number of subjects: 154
Study 24656949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Facts intervention (automated email messages promoting fruit and vegetable consumption every 3 days for 1 month)
Number of subjects: 162
Study 24656949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 22158262 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual feedback using Nintendo Wii Balance Boards (NWBBs)
Number of subjects: 47
Study 22158262 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 47
Study 20541069 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative β-blockade
Number of subjects: 0
Study 20541069 — intervention group
Group type: COMPARATOR
Intervention: Standard practice as per ACC/AHA guidelines
Number of subjects: 0
Study 17657327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological intervention with telephone monitoring (TM)
Number of subjects: 345
Study 17657327 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (TH)
Number of subjects: 345
Study 15757075 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 15757075 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin therapy)
Number of subjects: 0
Study 22072154 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir therapy (4 doses)
Number of subjects: 10
Study 10687258 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil 16 mg
Number of subjects: 128
Study 10687258 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 128
Study 8701872 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (0.5 mg/day) administered between >7 days before PTCA and 3 months after PTCA
Number of subjects: 118
Study 8701872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probucol)
Number of subjects: 118
Study 8701872 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (0.5 mg/day)
Number of subjects: 118
Study 8701872 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol blood concentration
Number of subjects: 118
Study 1341324 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy and selective radiotherapy to the brain for stage pT1-3N0M0 patients.
Number of subjects: 186
Study 1341324 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy for stage pT1-3N2M0 patients.
Number of subjects: 186
Study 1341324 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery for resectable tumors followed by postoperative chemotherapy.
Number of subjects: 186
Study 1341324 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by adjuvant surgery.
Number of subjects: 186
Study 6391495 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable gold
Number of subjects: 0
Study 6391495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gold
Number of subjects: 0